[go: up one dir, main page]

PL442602A1 - Method, use and set for detecting increased risk of breast cancer - Google Patents

Method, use and set for detecting increased risk of breast cancer

Info

Publication number
PL442602A1
PL442602A1 PL442602A PL44260222A PL442602A1 PL 442602 A1 PL442602 A1 PL 442602A1 PL 442602 A PL442602 A PL 442602A PL 44260222 A PL44260222 A PL 44260222A PL 442602 A1 PL442602 A1 PL 442602A1
Authority
PL
Poland
Prior art keywords
breast cancer
increased risk
detecting increased
genetic predisposition
new
Prior art date
Application number
PL442602A
Other languages
Polish (pl)
Inventor
Cezary Cybulski
Jan LUBIŃSKI
Dominika Wokołorczyk
Wojciech Kluźniak
Klaudia Stempa
Tomasz Huzarski
Jacek Gronwald
Tadeusz Dębniak
Original Assignee
Cezary Cybulski
Lubiński Jan
Pomorski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cezary Cybulski, Lubiński Jan, Pomorski Uniwersytet Medyczny filed Critical Cezary Cybulski
Priority to PL442602A priority Critical patent/PL442602A1/en
Publication of PL442602A1 publication Critical patent/PL442602A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Zgłoszenie opisuje sposób i produkty znajdujące zastosowanie w diagnozowaniu genetycznej predyspozycji do chorób u ludzi i polega na ocenie czy w materiale biologicznym badanej osoby występuje specyficzna zmiana konstytucyjna w genie ATRIP. Zgłoszenie dotyczy nowej metody diagnostycznej wykrywającej genetyczną predyspozycję do inwazyjnego raka piersi. Sposób i zestaw diagnostyczny dotyczy opracowania nowego markera dla raka piersi.The application describes the method and products used in diagnosing genetic predisposition to diseases in humans and involves assessing whether a specific constitutional change in the ATRIP gene occurs in the biological material of the examined person. The application concerns a new diagnostic method detecting a genetic predisposition to invasive breast cancer. The method and diagnostic kit relates to the development of a new marker for breast cancer.

PL442602A 2022-10-24 2022-10-24 Method, use and set for detecting increased risk of breast cancer PL442602A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL442602A PL442602A1 (en) 2022-10-24 2022-10-24 Method, use and set for detecting increased risk of breast cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL442602A PL442602A1 (en) 2022-10-24 2022-10-24 Method, use and set for detecting increased risk of breast cancer

Publications (1)

Publication Number Publication Date
PL442602A1 true PL442602A1 (en) 2024-04-29

Family

ID=90885597

Family Applications (1)

Application Number Title Priority Date Filing Date
PL442602A PL442602A1 (en) 2022-10-24 2022-10-24 Method, use and set for detecting increased risk of breast cancer

Country Status (1)

Country Link
PL (1) PL442602A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044214A2 (en) * 2001-11-20 2003-05-30 Baylor College Of Medicine Methods and compositions in checkpoint signaling

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044214A2 (en) * 2001-11-20 2003-05-30 Baylor College Of Medicine Methods and compositions in checkpoint signaling

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BORECKÁ, M.: "Ph.D. Thesis, Prague, 2020", "ROLE OF GENETIC FACTORS RESPONSIBLE FOR DEVELOPMENT OF PANCREATIC CANCER" *
KULIGINA, E. S. ET AL.: "Annals of Oncology, vol. 28, Supplement 5, September 2017, abstrakt", 25P "BREAST CANCER PREDISPOSING GERMLINE MUTATIONS IDENTIFIED BY EXOME SEQUENCING" *
ZHANG, J. ET AL.: "Mol Cancer Res. 2009 September; 7(9): 1510-1516", "PREVALENCE AND FUNCTIONAL ANALYSIS OF SEQUENCE VARIANTS IN THE ATR CHECKPOINT MEDIATOR CLASPIN (CLSPN)" *

Similar Documents

Publication Publication Date Title
Somiari et al. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer
Madsen et al. Epidermal growth factor and monocyte chemotactic peptide-1: potential biomarkers of urinary tract obstruction in children with hydronephrosis
Goutham et al. DNA double-strand break analysis by γ-H2AX foci: a useful method for determining the overreactors to radiation-induced acute reactions among head-and-neck cancer patients
Anderson et al. Sensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) assay: implications for improving cancer diagnostics
NZ712746A (en) Methods and systems for assessing clinical outcomes
Gomez-Brouchet et al. Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma
US20080234946A1 (en) Predictive radiosensitivity network model
Putra et al. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy
So et al. Emerging principles of cancer biophysics
WO2010051552A1 (en) Methods of simulating chemotherapy for a patient
PL442602A1 (en) Method, use and set for detecting increased risk of breast cancer
CN112067808B (en) Detection and application of a cervical cancer metastasis marker
Introcaso et al. Association of change in clinical status and change in the percentage of the CD4+ CD26− lymphocyte population in patients with Sezary syndrome
Winder et al. Impact of an online risk calculator for sentinel node positivity on management of patients with T1 and T2 melanomas
McCaig et al. Biomarkers for Human Donor Lung Assessment during Ex Vivo Lung Perfusion
Khattab et al. Estimation of neutrophil activation marker in lichen planus patients
US8163473B2 (en) Method for using DNA repair capacity as a biomarker of breast cancer risk in women
CN101405601A (en) Method of evaluating skin sensitivity level by using squamous cell carcinoma-related antigen as indication
US20230131016A1 (en) Methods for disease assessment using drain fluid
Zhang et al. Integration of flow cytometry and computational analysis to dissect the epidermal cellular subsets in keloids that correlate with recurrence
EP4232821B1 (en) Dna damage sensitivity as a new biomarker for detection of cancer and cancer susceptibility
Malaina et al. Metastasis of cutaneous melanoma: risk factors, detection and forecasting
Lewier et al. Analysis of Drug Logistics Planning at Medical Management Agency in Ambon City Health Office (Qualitative study)
Navas et al. Inflammatory Foot Dermatoses: The Correlation Among Morphological Patterns, Histopathological Findings, and Patch Test Positivity
Faram et al. 10 YEAR REVIEW OF CHRONIC GRANULOMATOUS INflAMMATORY REACTIONS FOUND IN THE ORAL CAVITY: 2007-2016